Genmab A/S has grown revenue 37% a year over three years and 32% a year over five, with earnings per share compounding at −43%. Revenue growth, 3-year annual rate: +37% (Biotechnology median +21%). Revenue growth, 5-year rate: +32%, growth has picked up over the last three years. Earnings per share, 3-year rate: −43%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 9, FY2017 to FY2025, as filed.

GMABGenmab A/S

HealthcareUSD

$33.75

$21.0852 weeks$35.34

Is it growing?

Is GMAB growing?

Genmab A/S has grown revenue 37% a year over three years and 32% a year over five, with earnings per share compounding at −43%.

+37%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +32%
Revenue growth, 5-year rate · +37% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −43%
Earnings per share, 3-year rate · revenue +37% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed